Every RUO vendor's certificate of analysis, scored against a 5-check framework. Public-COA scoring only — independent identity testing rolling out Q3 2026. The reclassification fight does not matter if the COA is a sticker.
Methodology disclosed below. Conflict disclosure: published by Colby Watkins, who also operates heroxbio.com (an RUO peptide vendor; same scoring framework applied).
| Vendor | Compound | Last batch | Check 1 Lab+accred |
Check 2 ID+purity |
Check 3 Batch dated |
Check 4 Method named |
Check 5 Lot traceable |
Verdict | Notes |
|---|
The COA Truth Index scores publicly available certificates of analysis from RUO peptide vendors. Each vendor row reflects the most recent COA published on the vendor's product page or accessible by direct URL. Scoring applies a 5-check framework derived from BTLabs identity-test methodology and standard pharmaceutical document review.
PASS = 5/5 checks. PARTIAL = 3-4/5. FAIL = 0-2/5. PENDING = COA not yet reviewed; placeholder row for tracking.
This is not independent identity testing. The Compound Brief publishes scores based on the documents vendors themselves publish. A vendor passing 5/5 here does not mean the vial contains what the label claims — it means the documentation is internally consistent and methodologically defensible. Independent vial identity testing rolls out Q3 2026 as a separate quarterly report.
This is not a buy guide. RUO peptides are sold for research purposes only; nothing here is a recommendation to use them on humans or animals. See the full disclaimer below.
The Compound Brief is published by Colby Watkins, who also operates heroxbio.com — an RUO peptide vendor. heroxbio is scored on the Index against the same 5-check framework as every other vendor, and is required to disclose any score adjustment publicly. If the Index ever appears to favor heroxbio against the literal scoring, call it out by reply at colby@whbiopharma.com. The Index dies the day operators can't trust the read.